Shopping Cart
- Remove All
- Your shopping cart is currently empty
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity. |
Targets&IC50 | CDK2:0.27 μM |
In vitro | CDK2/PIM1-IN-1 (Compound 6b) exhibits antiproliferative effects on MCF7 (IC50: 5.54 μM), HCT-116 (IC50: 2.62 μM), HepG2 (IC50: 3.99 μM), and HeLa cell lines (IC50: 8.31 μM), with moderate safety in normal breast cell line MCF-10A (IC50: 39.44 μM). In HCT116 cells, CDK2/PIM1-IN-1 (24 hours) inhibits the G0-G1 phase (%G0-G1: 83.43%) and induces significant early (8.28%) and late (20.09%) apoptosis. It also inhibits CDK (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM) within the HCT116 cell line. |
In vivo | CDK2/PIM1-IN-1 (Compound 6b), administered at 10 mg/kg intraperitoneally three times a week for two weeks, effectively reduces tumor volume by 71.42% and tumor weight by 70.58% in a solid Ehrlich carcinoma (SEC) mouse model while demonstrating good tolerability. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.